Who are AZD7442's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casirivimab and Imdevimab Drug Combination, Lilly Bamlanivimab + Etesevimab, SCB-2019/Clover, BRII-196, BRII-196/BRII-198, daclizumab, infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd7442.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AZD7442 — Competitive Intelligence Brief

AZD7442 (AZD7442) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody combination. Area: Infectious Disease / Virology.

phase 3 Monoclonal antibody combination SARS-CoV-2 spike protein receptor-binding domain Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

AZD7442 (AZD7442) — AstraZeneca. AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD7442 TARGET	AZD7442	AstraZeneca	phase 3	Monoclonal antibody combination	SARS-CoV-2 spike protein receptor-binding domain
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
Lilly Bamlanivimab + Etesevimab	Lilly Bamlanivimab + Etesevimab	Erin McCreary	marketed	Monoclonal antibody combination (neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
SCB-2019/Clover	SCB-2019/Clover	D'Or Institute for Research and Education	phase 3	Recombinant protein vaccine	SARS-CoV-2 spike protein receptor-binding domain (RBD)
BRII-196	BRII-196	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Monoclonal antibody (neutralizing)	SARS-CoV-2 spike protein receptor-binding domain (RBD)
BRII-196/BRII-198	BRII-196/BRII-198	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Monoclonal antibody combination	SARS-CoV-2 spike protein receptor-binding domain
daclizumab, infliximab	daclizumab, infliximab	University of Iowa	marketed	Monoclonal antibody combination	IL-2 receptor alpha (CD25) and TNF-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody combination class)

AstraZeneca · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
The First People's Hospital of Changzhou · 1 drug in this class
University of Iowa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD7442 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd7442. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab